GSK, Theravance report Ph3 successes for COPD treatment

GlaxoSmithKline and Theravance are giving analysts a thumbs-up on their late-stage studies of Relovair, the next-gen COPD successor to Advair. Investigators say that the drug bested a placebo in the trials. A head-to-head trial pitting Relovair against Advair is underway. "Successful completion of these two studies is an important milestone in the development of Relovair for COPD," said Darrell Baker, head of Glaxo's respiratory medicine development program. "These data will be reviewed together with the larger 12-month exacerbation studies still under way, to develop a complete evaluation of Relovair in treating patients with COPD." Report

Suggested Articles

MicuRx nabbed $7.78 million from a nonprofit focused on antimicrobial resistance to push its third antimicrobial program into human trials.

The FDA has handed Scholar Rock a rare pediatric disease designation voucher, which can allow the biotech a speedy review of its SMA med.

The FDA has placed a phase 1/2 trial of Passage Bio’s GM1 gene therapy on clinical hold pending further assessment of the risk of its delivery device.